Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025

Feb. 04, 2025 11:34 AM ETRegeneron Pharmaceuticals, Inc. (REGN) StockAI-Generated Earnings Calls Insights6 Comments
(5min)

Earnings Call Insights: Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2024

Management View

  • CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected in 2025, driven by anticipated FDA approvals
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

About REGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
REGN--
Regeneron Pharmaceuticals, Inc.